Publications
187
Citations
7,159
Est. group size
—
Recurring co-author estimate
Active years
32
Publishing since 1995
Cheryl T. Lee's research centers on bladder cancer, particularly the surgical management of urothelial cancer, radical cystectomy outcomes, and biomarkers to predict disease progression. Her work also addresses patient quality of life, recovery, and prehabilitation before surgery, as well as equity and diversity in urologic and prostate cancer care. This research combines clinical/surgical oncology with health services and quality-of-life studies relevant to cancer patients.
Publication output has fluctuated over the past decade, with a peak in 2023 followed by a decline, and the 5-year average of under 5 papers per year suggests a somewhat slowing recent pace.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Enhancing Graduate Surgical Education: Recommendations for Development of Common Surgery Education and Training Accreditation Standards
Annals of Surgery Open · 2026
- Abstract 3941: A RHO GTPase pathway signature as a potential prognostic biomarker and therapeutic target in bladder cancer.
Cancer Research · 2026
- Optimizing local control in the surgical management of bladder cancer
Nature Reviews Urology · 2025
- Paradigm Shifting Research: Key Studies in Urologic Oncology
Annals of Surgical Oncology · 2024
- Data from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Supplementary Methods, Figures 1-7 from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Supplementary Figure 1 from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Supplementary Figure 2 from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Supplementary Figure 1 from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Supplementary Figure 2 from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Supplementary Methods, Figures 1-7 from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Data from Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer
2023
- Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care
European Urology · 2022
- Associations of self‐efficacy, social support and coping strategies with health‐related quality of life after radical cystectomy for bladder cancer: A cross‐sectional study
European Journal of Cancer Care · 2022
- PD14-11 USE OF A PHYSICAL ACTIVITY MONITOR TO TRACK PERIOPERATIVE ACTIVITY OF RADICAL CYSTECTOMY PATIENTS: OUR FIRST GLIMPSE AT WHAT OUR PATIENTS ARE REALLY DOING BEFORE AND AFTER SURGERY
The Journal of Urology · 2022
- Journal of Clinical Oncology×6
- The Journal of Urology×6
- Urology×6
- Journal for ImmunoTherapy of Cancer×3
- Urologic Oncology Seminars and Original Investigations×3
- Kamal S. Pohar
Medicine · The Ohio State University
- Hristos Z. Kaimakliotis
Medicine · Indiana University
- Courtney Yong
Medicine · Indiana University
- Daniel Sidhom
Medicine · Indiana University
- Debra L. Zynger
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile